Recent Developments in Immunotherapy of Cancers Caused by Human Papillomaviruses.

Recent Developments in Immunotherapy of Cancers Caused by Human Papillomaviruses. Immunology. 2020 Nov 18;: Authors: Fakhr E, Modic Ž, Cid Arregui A Abstract A subset of oncogenic human papilloma viruses (HPVs) is the main cause of genital cancers, most importantly cervical cancer, as well as an increasing number of head and neck cancers. Despite the availability of prophylactic vaccines against the most prevalent oncogenic HPV types, HPV-induced malignancies are still a major health and economic burden. Besides conventional treatment with surgery, chemotherapy and radiation, immunotherapy is emerging as an efficient adjuvant option. Here we review relevant studies and ongoing clinical trials using immune checkpoint inhibitors, therapeutic vaccines, gene editing approaches and adoptive T cell therapies, with special focus on engineered-TCR T cells, which are showing encouraging results and could lead to significant improvement in the treatment of HPV+ cancer patients. PMID: 33205441 [PubMed - as supplied by publisher]
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research